BR0111987A - Método para a detecção de um complexo de proteìna de fase aguda de lipoproteìna e previsão de um risco maior de falência do sistema ou mortalidade - Google Patents

Método para a detecção de um complexo de proteìna de fase aguda de lipoproteìna e previsão de um risco maior de falência do sistema ou mortalidade

Info

Publication number
BR0111987A
BR0111987A BR0111987-7A BR0111987A BR0111987A BR 0111987 A BR0111987 A BR 0111987A BR 0111987 A BR0111987 A BR 0111987A BR 0111987 A BR0111987 A BR 0111987A
Authority
BR
Brazil
Prior art keywords
patient
acute phase
mortality
predicting
detecting
Prior art date
Application number
BR0111987-7A
Other languages
English (en)
Inventor
Timothy J Fischer
Colin Downey
Mike Nesheim
John A Samis
Liliana Tejidor
Cheng Hock Toh
John B Walker
Original Assignee
Bio Merieux Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Merieux Inc filed Critical Bio Merieux Inc
Publication of BR0111987A publication Critical patent/BR0111987A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO PARA A DETECçãO DE UM COMPLEXO DE PROTEìNA DE FASE AGUDA DE LIPOPROTEìNA E PREVISãO DE UM RISCO MAIOR DE FALêNCIA DO SISTEMA OU MORTALIDADE". Método para diagnóstico de uma condição de um paciente que envolve as etapas de: a) adição de um ou mais reagentes a uma amostra de teste de um paciente, as amostras de teste compreendendo pelo menos parte de uma amostra de sangue do paciente a fim de causar formação de um complexo compreendendo pelo menos uma proteína de fase aguda e pelo menos uma lipoproteína humana, enquanto não causando substancialmente nenhuma polimerização de fibrina; b) medição da formação do dito complexo com o tempo de modo a se obter um perfil de medição dependente do tempo; e c) determinação de uma inclinação e/ou mudança total no perfil de medição dependente do tempo de modo a diagnosticar uma condição do paciente. Uma formação maior do complexo está correlacionada com a maior probabilidade de morte do paciente.
BR0111987-7A 2000-06-09 2001-06-08 Método para a detecção de um complexo de proteìna de fase aguda de lipoproteìna e previsão de um risco maior de falência do sistema ou mortalidade BR0111987A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59164200A 2000-06-09 2000-06-09
PCT/US2001/018611 WO2001096864A2 (en) 2000-06-09 2001-06-08 A method for detecting a lipoprotein-acute phase protein complex

Publications (1)

Publication Number Publication Date
BR0111987A true BR0111987A (pt) 2003-10-28

Family

ID=26680497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111987-7A BR0111987A (pt) 2000-06-09 2001-06-08 Método para a detecção de um complexo de proteìna de fase aguda de lipoproteìna e previsão de um risco maior de falência do sistema ou mortalidade

Country Status (10)

Country Link
US (1) US20070155018A1 (pt)
EP (1) EP1309857B1 (pt)
JP (1) JP5051960B2 (pt)
AT (1) ATE302947T1 (pt)
AU (2) AU6679501A (pt)
BR (1) BR0111987A (pt)
CA (1) CA2412317C (pt)
DE (1) DE60112949T2 (pt)
MX (1) MXPA02012176A (pt)
WO (1) WO2001096864A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003073099A1 (en) 2002-02-27 2003-09-04 Biomerieux, Inc. Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome
MXPA05005031A (es) 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
CA2505843A1 (en) 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
EP1828783A1 (en) * 2004-12-01 2007-09-05 BioMerieux, Inc. Method for diagnosing critically ill patients
CA2605143A1 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
JP5125608B2 (ja) * 2008-02-28 2013-01-23 東ソー株式会社 イオン交換クロマトグラフィーによる血液中のＬｐ（ａ）の分離方法
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
GB201223079D0 (en) 2012-12-20 2013-02-06 Sepsis Ltd Point of care sepsis assay device and method
GB201301611D0 (en) * 2013-01-30 2013-03-13 Shaw Andrew M Systems and methods for medical data processing and analysis
GB202004047D0 (en) 2020-03-20 2020-05-06 Ainger Phill Point of care sepsis assay device and method
CN113252852B (zh) * 2021-06-04 2021-10-22 金科环境股份有限公司 絮凝剂性能评价与检验设备及方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708591A (en) * 1995-02-14 1998-01-13 Akzo Nobel N.V. Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions
US6429017B1 (en) * 1999-02-04 2002-08-06 Biomerieux Method for predicting the presence of haemostatic dysfunction in a patient sample

Also Published As

Publication number Publication date
ATE302947T1 (de) 2005-09-15
DE60112949D1 (de) 2005-09-29
WO2001096864A3 (en) 2003-02-06
EP1309857A2 (en) 2003-05-14
AU2001266795B2 (en) 2006-07-13
CA2412317A1 (en) 2001-12-20
CA2412317C (en) 2016-03-22
JP2004503254A (ja) 2004-02-05
AU6679501A (en) 2001-12-24
US20070155018A1 (en) 2007-07-05
WO2001096864A2 (en) 2001-12-20
JP5051960B2 (ja) 2012-10-17
DE60112949T2 (de) 2006-05-18
MXPA02012176A (es) 2004-08-19
EP1309857B1 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
Harenberg et al. Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC dipstick
NO20000970L (no) Fremgangsmõte og utstyr for rask analyse av analytter i biologiske stikkprøver
DE69910003D1 (de) Überwachung physiologischer analyte
DE69910007D1 (de) Vorrichtung zum vorhersagen von physiologischen messwerten
DE60128249D1 (de) Verfahren zur diagnose von immunologischer lebensmittelsensitivität
DE60238814D1 (de) Integriertes blutprobemessgerät mit teststreifen
DK1421215T3 (da) Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
BR0111987A (pt) Método para a detecção de um complexo de proteìna de fase aguda de lipoproteìna e previsão de um risco maior de falência do sistema ou mortalidade
EA200600893A1 (ru) Определение гематокрита и концентрации аналита
BR9609771A (pt) Processo para medição quantitativa de proteìna amilóide a; proteìna recombinante; anti-soro especìfico de soro humano de fase aguda.
RU2008103988A (ru) Способ диагностики рассеяного склероза
Dargaud et al. Global haemostasis and point of care testing
Lutteri et al. Evaluation of the new Sebia free light chain assay using the AP22 ELITE instrument
EA202192954A1 (ru) Электрохимическое измерение d-лактата для диагностики и прогнозирования инфекционного заболевания
Joist Hypercoagulability: introduction and perspective
JP2021510815A5 (pt)
ATE314648T1 (de) Diagnostisches verfahren für asthma
EP0992213A1 (en) Method for calibration and measurement in a micro-dialysis system
AU768436B2 (en) Method and apparatus for presenting thrombosis and hemostasis assay data
HUP0100948A2 (hu) Antitest kompeticiós teszt (AKT) P-glikoprotein és egyéb sejtfelszíni receptorok, pumpák és fehérjék konformáció-változásainak kvalitatív, illetve konformáció-függő kvantitatív kimutatására és annak alkalmazásai
DE60102245D1 (de) Anhand der konduktivität normalisierte bestimmung von analyten in urin zur diagnose von krankheiten
Gedikbasi et al. New generation oral anticoagulants may cause unreliable results in routine coagulation testing
Kang et al. Changes of Pepsin Concentration in Saliva Sample According to Storage Period
Burger et al. Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator. Diagnostics 2023, 13, 2128
DE69929817D1 (de) Verfahren zur aktivitätsbestimmung einer substanz mittels eines funktionellen in vitro tests

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009.